Ryverna Solution for Infusion

Introduction

Ryverna is a prescription medication that contains the active ingredient Crizanlizumab. It is available in solution form and is prescribed to treat certain conditions.

Uses

Ryverna is primarily used to prevent vaso-occlusive crises in patients with sickle cell disease. Vaso-occlusive crises are painful episodes caused by the blockage of blood vessels by sickle-shaped red blood cells. By targeting a specific protein involved in this process, Crizanlizumab helps reduce the frequency of these crises.

Dosage and Administration

Ryverna is administered as an intravenous infusion. The recommended dosage for adults is 5 mg/kg, given over a 30-minute period, every four weeks. The actual dosage and frequency may vary based on individual patient factors, such as age, weight, and response to treatment. Follow the instructions provided by your healthcare provider.

Mechanism of Action

Crizanlizumab, the active ingredient in Ryverna, works by binding to a protein called P-selectin, which is involved in the adhesion of sickle cells to blood vessel walls. By blocking this interaction, Crizanlizumab helps prevent the formation of blood clots and reduces the frequency of vaso-occlusive crises in patients with sickle cell disease.

Side Effects

Common side effects may include headache, nausea, back pain, joint pain, and fever. These side effects are usually mild and temporary. However, if you experience any severe or persistent side effects, such as severe allergic reactions, chest pain, or difficulty breathing, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. Certain medications may interact with Ryverna, potentially affecting its effectiveness or increasing the risk of side effects. Your healthcare provider will consider these potential interactions and adjust your treatment plan accordingly.

Precautions

Before using Ryverna, inform your healthcare provider about any medical conditions you have, especially if you have a history of bleeding disorders or infections. Additionally, inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding, as the safety of this medication during pregnancy and breastfeeding has not been established.

Storage

Ryverna should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Do not freeze the solution. Keep the medication in its original container and out of reach of children.

Patient Tips

• Follow the dosage instructions provided by your healthcare provider.
• Keep all scheduled appointments for infusion administration.
• Inform your healthcare provider about any side effects or concerns you may have.
• Store the medication properly in the refrigerator.
• If you have any questions or concerns, do not hesitate to contact your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Crizanlizumab (Drugs.com) [Accessed 12 Jun. 2024] (online) Available at:
• crizanlizumab-tmca 10 mg/ml intravenous solution (RX) [Accessed 22 Jun. 2024] (online) Available at:
• Crizanlizumab-tmca Injection (MedlinePlus) [Accessed 15 Jun. 2024] (online) Available at:
• Blair HA. Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84. doi: 10.1007/s40265-019-01254-2. [Accessed 22 Jun. 2024] Available at: